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Glutathione S-transferase (GST) enzyme activity, GST 
isoenzyme composition and glutathione (GSH) concentra­
tion were assessed in normal and squamous cell carcinoma 
specimens of 14 patients with oral or oropharyngeal cancer 
and 11 patients with laryngeal cancer. Comparing malig­
nant with normal oral/oropharyngeal tissues, no significant 
differences in GSH content, GST enzyme activity or iso­
enzyme composition were found. However, some tumours 
had up to 3-fold increased GST enzyme activities and
11 malignant samples over-expressed GST-tc. GST-tc was 
present in all normal and malignant oral/oropharyngeal 
specimens investigated, whereas class a  and class \i were 
detected in only a few samples. GST-fj. was present in 
28% of the patients with oral/oropharyngeal tumours as 
compared with -60% in the normal population. GST-a, -|i 
and -71 were detected in 91, 64 and 100% of the normal 
laryngeal tissues respectively. In laryngeal tumours signi­
ficantly higher levels of GST-tc and GSH but signi­
ficantly lower amounts of GST-a were detected. Levels of 
class p GST were generally lower in cancerous tissues, but 
differences were not significant. In comparison with normal 
oral/oropharyngeal tissues, normal laryngeal tissues con­
tained almost twice the amount of GST enzyme activity 
due to higher class a  enzyme levels. It is concluded that 
(ÏST-7C is elevated in 11 out of 14 tumours of the oral cavity 
and values are significantly increased in tumours of the 
larynx, which may contribute to the inherent anti-cancer 
drug resistance of these malignancies. In laryngeal tumours 
the increased GSH levels may confer additional resistance 
to radiation therapy.
Introduction
Oral/oropharyngeal and laryngeal cancers account for 2.1 and
1.3 cancer deaths per 100 000 population/year respectively in 
'Fhe Netherlands (1). Alcohol consumption and smoking have 
been implicated as causative factors in the development of 
these tumours. Early involvement of regional lymph nodes 
lends to occur in patients with these types of cancers. Chemo­
therapy, usually added for the treatment of extensive disease, 
is of limited use in oral/oropharyngeal and laryngeal cancer 
due to either intrinsic resistance or development of (multi-drug) 
resistance during treatment with chemotherapeutic drugs (2,3).
'Fhe mechanisms involved in drug resistance are poorly 
understood. In vitro studies with tumour cell lines selected for 
resistance to commonly used chemotherapeutics demonstrated 
that several interrelated mechanisms may be involved in
♦Abbreviations: GST, glutathione S-lransierase; GSH, glutathione.
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the acquisition of the drug resistant phenotype. Decreased 
intracellular drug accumulation by increased expression of the 
P I70 glycoprotein drug efflux pump (4), increased repair or 
tolerance to drug-induced damage by over-expression of DNA 
topoisomerases (5) and high metabolic drug inactivation by 
conjugation with glutathione (GSH*) (6) are all considered to 
contribute to the observed resistance.
Glutathione S-transferases (GSTs) are enzymes which cata­
lyse the nucleophilic addition of GSH to electrophilic centres 
of a wide variety of compounds. This reaction is the first step 
in the formation of mercapturic acids, a pathway mostly 
resulting in the elimination of potentially toxic compounds 
(7,8). GSTs are also involved in the meta bolism of several 
types of anti-cancer drugs and are over-expressed in many 
human refractory tumours (9). In cell lines resistant to anti­
cancer drugs as diverse as alkylating agents, anthracyclines 
and c/s-platinum, increased GST and GSH concentrations have 
been implicated as resistance mechanisms [see Tsuchida and 
Sato (9) for review and references]. High GSH and/or GST 
levels in tumours may therefore be a barrier to an effective 
treatment with chemotherapeutics. Based on structural, 
physicochemical, enzymatic and immunological properties, 
cytosolic GSTs are divided into three classes: a , jLt and % (8). 
Recently a fourth class of GST (0) has been described (10). 
The predominant form present in most investigated human 
tumours is class % GST and comparison of matched pairs of 
normal and malignant tissues revealed elevated levels in 
stomach, colon, bladder, cervix and lung tumours (9,11-13).
Since different classes of GSTs have distinct substrate 
specificities, GST subclass composition may influence the 
detoxifying ability of tissues (8). Therefore we examined GST 
activity, GST isoenzyme composition and GSH levels in 
squamous cell carcinoma and corresponding normal epithelium 
of 14 patients with oral/oropharyngeal carcinoma and in 11 
patients with laryngeal carcinoma.
Materials and methods
Tissue samples
Twenty-five patients with oral/oropharyngeal or laryngeal squamous cell 
carcinoma were operated upon at the Department of Otorhinolaryngology and 
Maxillofacial Surgery of the University Hospital St Radboud. All patients 
received primary surgical treatment. Patient data are given in Table I. 
Representative parts of tumour and adjacent non-malignant mucosal tissue 
were excised by a pathologist. From six patients samples of neck lymph node 
métastasés were obtained from the same resection specimen. The neck 
metastasis of patient no. 4 occurred 5 months after resection of the primary 
tumour and was removed by radical neck dissection.
All tissue samples obtained were frozen within 20 min after resection of 
the tumour and stored at —70°C. Tissue fragments (10—100 mg) were thawed 
and homogenized on ice in 5 volumes of homogenizing buffer (250 mM 
sucrose, 20 mM Tris-H C l, i mM dithiothreitol, pH 7.4) using small 
glass—glass homogenizers. The homogenates were centrifuged at 150 OOOXg 
at 4°C for 1 h. Supernatants (cytosolic fractions) were divided into portions
and stored at —70°C.
Assays
Protein was assayed by the method of Lowry et a l  (15). GST enzyme activity 
with l-chloro-2,'4-di nitrobenzene as substrate by the method of Habig et a l
619
T.PJ.Mulder et ai
Table I. Patient and tumour characteristics
Patient number Age Gender Site of primary tumour Classification9 Differentiation grade Metastatic
tumour tissue available
Patients with oral/oropharyngeal tumours
I 54 M Tonsil pTiN()M() Moderale —
n 6 b M Tongue pTiN()M(, Moderale —
3 64 M Moor of mouth PT: N()M0 Moderate
4 60 F Tongue Well
5 70 M Floor of mouth pT.,N2aM() Moderate —
6 61 M Hase of longue pT2N,M„ Moderate -f-
7 61 M Base of tongue pTiNiMo Moderate —
8 74 M Base of toni'ue pT.iN2bM<) Moderate
9 66 M Tongue pTiNjMo Moderate i"~>
10 47 M Lateral pharynx wall pTnN„M„ Moderate
11 59 M Base of tongue pT2N()Mn Moderate —
12 60 M Floor of monili pT.,N()M() Moderate 1
13 65 M Lateral pharynx wall pT.,N()M(, moderate -------------
14 65 M Lateral pharynx wall pT2NnMn Poor
Patients with laryngeal tumours
15 57 M Transglotiic pT.tN-,aMu Poor - \ -
16 84 M Supraglottie pT.|N(,M() Poor
17 61 M Supraglotlic pT.,NuM„ Poor
18 66 M Supraglotlic pT4NiaMn Moderate
19 65 M Glottic pT,N2aM(l Moderate
20 62 M Supraglotlic pT.jNi.Mji Moderate
21 63 M Supraglottie pT.,N,M(l Moderate
m 72 M Tttmsgloliie pT.jNnMj) Moderate * * * *  4
69 M Supraglotlic pT,N2aMu Moderate 1
24 60 M Supraglotlic PT.iN,cMu Moderate I
25 49 M Supraglotlic pT,N0M(1 Moderate «  •
“Staging according to the International Union Against Cancer Classification (14), 
llNeck metastasis was removed 5 months alter resection of the primary tumour.
(16). Total GSM was quantised by high performance liquid chromatography 
as described by us recently (17). GSTs class u, j.t and it were quantilied in 
cytosolic fractions by densilometrie analyses of immunohlois, essentially as 
described before (12). The eoelìieient o f variation of this method is U M .W . 
Class «  antibodies react against GST A M ,  GST AI-2 and GST A2~2 112), 
class (i antibodies recognize GST M la-ln . (ÌST M la - lb  and GST M lb-lh
( I8 J 9 )  and class k antibodies are directed against (ïST IM- 1 (20). ('ross- 
reactivity of the above-mentioned monoclonal antibodies with recently disco­
vered (i.e. GST M2-M5) or yet unknown GST isoforms cannot be excluded.
Calcukuians am! statistical analyses
Total GSH was calculated as nmol/mg protein. Concentrations of GST 
subclasses were calculated as Hg/mg total cytosolic protein. Values below the 
detection limit ol the immunoblot assays (~0.()2 pg/mg protein) were evaluated 
as /ero.
Wilcoxon’s matehed-pairs signed-ranks test was used to evaluate différences 
between pairs of normal and malignant tissue. Differences between non-paired 
samples were analyzed using the Mann Whitney ¿/-lest. Correlations between 
the parameters were tested with Pearson's linear correlation procedure. 
Differences were considered significant if the l } value was • 0.05.
Results
Oral cavity and oropharynx
In most normal and squamous ceil carcinoma specimens GST- 
a  levels were below the detection limit ('Fable II).
Four patients (2L)%) expressed GST-jli in normal as well as 
in malignant tissue and these tumours contained less GST-¡i 
than the surrounding normal tissue.
GST-tc was by far the major subclass present and accounts 
for 92 and 97% of the cytosolic GST protein in normal and 
malignant tissues respectively. GST-tc content was higher in 
the tumours of 11 out of 14 pairs of samples and the 
mean tumour value was also hiuher (3.57 ± 0.61 versus
Vi*
2.7X ± 0.37 Jig/mg protein in normal tissue), but the difference 
was not significant iP 0.12).
Mean GST activity was higher in the malignant tissues (291 
± 66 versus 195 ± 23 nmol/min/mg protein in normal tissues) 
and tumour GST activities were higher in the same í 1 patients 
with increased tumour GST-tc levels. However, differences 
were not signiiìcant (P = 0,08).
Most tumours (10/14) contained less GSH than the matched 
normal tissue, resulting in a slightly lower mean GSH concen­
tration in the tumours (26,9 ±  1.6 versus 30.5 ± 3.0 nmol/ 
mg protein in normal epithelium), but differences were not 
significant (P — 0.25).
'Fhe two lymph node métastasés investigated were similar 
to the corresponding primary tumour in all aspects analyzed.
Larynx
»
Mean GST-a levels were lower in tumours (0.26 ± 0.17 
versus 1.38 ± 0.43 |.tg/mg protein in normal mucosa) and in 
nine of the 11 pairs the tumour contained less GST-a than the 
normal mucosa (Table ill, P <  0.05).
GST-JJ. was expressed in six patients (55%) and in live of 
these patients the tumour contained less GST-p than the 
surrounding normal tissue, but the difference was not significant 
(/> 0.18).
GST-tc was the predominant GST subclass detected in all 
sani pi es and accounts for 63 and 89% of the total GST protein 
in normal tissues and tumours respectively. All except one 
carcinoma contained higher GST-tc concentrations than the 
matched normal tissue (P <  0.01) and mean GST-tc level was 
higher in tumour tissue (4.67 ± 0.47 versus 3.31 ± 0.39 jag/ 
mg protein in normal mucosa).
Mean GST activity in laryngeal tumours was higher than in 
surrounding normal tissues (495 ± 73 versus 382 ± 73 nmol/ 
min/mg protein respectively), but no significance was reached 
(/> 0.47),
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Table II. GST activity, GST isoenzyme level and GSH concentration in cytosols of oral/oropharyngeal tumours, corresponding normal tissues and métastasés
Patient number Tissue GST GSH (nmol/mg
’ ■ “ -------- ----------------------------------------------------------------------------------------- protein)
Activity (nmol/min/ Content (jug/mg prorein)
mg protein;
a K
1 N 320 — - 3.68 36.0
T 131 — — 1.66 23.5
2 N 84 — — 1.25 17.4
T 135 — - 1.71 30.2
3 N 182 0.07 — 1.81 29.8
T 245 0.05 — 2.70 23.6
4 N 168 — 0.61 2.46 29.2
T 191 0.09 0.17 3.26 24.4
M 166 — 0.43 2.87 32.7
5 N 195 0.03 — 2.64 27.3
T 438 0.05 — 4.20 31.7
6 N 228 — 1,05 1.27 32.9
T 307 — 0.93 2.94 24.2
M 183 — 0.44 2.03 20.6
7 N 98 — 1.84 1 1 . 0
T 143 — _ 2.06 28.0
8 N 204 — 0.56 2.58 23.3
T 211 — 0.15 2.79 35.2
9 N 166 — 1.12 1.02 23.0
T 226 — 0.25 2.32 19.1
10 N 79 — — 2.81 40.7
T 150 — — 3.32 26.4
11 N 181 — — 4.29 48.6
T 511 — — 8.26 32.5
12 N 322 — — 5.44 48.9
T 233 — — 3.97 32.9
13 N 154 — — 2.87 20.9
T 104 — — 1.80 13.1
14 N 355 — — 5.00 38.2
T 1053 — 8.97 31.7
Mean ±  SEM N I95±23 0.01 ± 0.01 0 .24± 0 .il 2.78±0.37 30.5±3.0
T 291 ± 6 6 0.01 ± 0.01 0.11 ±0.07 3.57±0.61 26.9+1.6
N, normal tissue; T, tumour; M, metastasis; - ,  not detectable.
Values are given as mean ± % standard error of the mean.
Mean GSH concentration in laryngeal tumours was 
almost twice as high as in normal tissues (40.9 ±  4.9 versus 
23.6 ±  5.2 nmol/mg protein respectively) and in nine of the 
10 matched pairs the tumour contained more GSH (P < 0.05).
GST subclass composition as well as GST activity and GSH 
concentration in four of the five lymph node métastasés were 
similar to primary tumours. However, one metastasis (patient 
no. 15) contained very high levels of GSH, GSTLji and GST- 
71: and consequently had a high GST enzyme activity.
Comparison o f normal laryngeal with normal oral/orophafyn- 
geal epithelium
In contrast to normal oral/oropharyngeal mucosa samples, 
GST-a was detected in all samples of normal laryngeal mucosa 
CP <  0.001, Tables II and III). In addition, laryngeal mucosae 
contained significantly more GST enzyme activity than oral/ 
oropharyngeal tissues (P <  0.001). GST-|i, GST-tc and GSH 
concentrations in normal laryngeal mucosae were not signi­
ficantly different from those in normal oral/oropharyngeal 
mucosae.
GST activity measured in all samples correlated well with 
calculated GST activities (Figure 1). Calculations were based 
on the isoenzyme levels determined by immunoblot and 
assuming specific activities (with l-chloro-2,4-dinitrobenzene 
as substrate) of 187, 105 and 64 |imol/min/mg protein for 
class ji, it and a  respectively (8).
Discussion
Calculated GST enzyme activities, based on GST subclass 
levels quantified on immunoblot, demonstrated a good linear 
correlation with the measured GST enzyme activities. More­
over, the slope of the regression line was ~1, indicating that 
almost ail GST activity towards 1-chloro-2,4-dinitrobenzene 
in the cytosolic fractions was accounted for by GST subclass 
immunoreactivity on Western blots. The failure to pass the 
origin may be due to underestimation of the highest calculated 
GST activities.
Normal laryngeal mucosae had significantly higher GST-a 
concentrations and GST enzyme activities than normal oral/ 
oropharyngeal samples. Mean GST-|i and GST-TC levels were 
also higher in normal laryngeal mucosae, whereas GSH levels 
were higher in normal oral/oropharyngeal samples, but differ­
ences were not significant.
Teicher et al. (21) developed a cw-platinum-resistant head 
and neck squamous cell carcinoma cell line which, among 
other changes, displayed an increased GST activity. Numerous 
cell lines selected for resistance towards common chemothera­
peutic drugs over-express GSTs. In addition, many refractory 
tumours have higher GST activities than the normal tissues they 
originated from (9). Since GSTs are involved in metabolizing 
several clinically relevant anti-cancer drugs (6), it has been 
suggested that increased GST concentrations may account for
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15 N 279 1.37 u .()0 2.0X 17.f t
T 354 ---- 0.31 3.67 3.1.3
M 1752 2.94 12.77 140.8
16 N 405 1.58 0.30 3.53 ND
T 397 O.Ofi 0.07 3 92 39.0
17 N 596 1.40 1 ">7^  1 ^  ? 4.14 28.6
T 570 0,40 1.43 4.89 32.2
IS N 540 i  SS • - 5.68 22.8
T 381 6.75 78.1
M 339 6.22 64.7
jy N 389 0.16 1.46 1.75 13.8
r j * 178 0.10 2.44 24.2
M 260 * 1.50 2.88 40.8
20 N 536 4.99 4.80 55.6
T 512 — • 5.43 35.9
21 N 381 1.47 2.81 23.1
T n i — 2.42 26.4
n4M M N 274 1.16 0.13 2.90 6.3
T 765 0.36 1.04 4.52 41.6
23 N 233 n <■«* 0.44 2.62 17.0
T 1038 l.KS —- 7.20 39.5
M :? 6 — 3.95 0.0
24 N 207 0.38 1.90 5.2
T 332 4.30 43.7
M 199 — ---- 2.36 42.0
25 N 371 0.16 1.17 4.25 46.4
T 600 0.17 0.39 5.88 52.0
Mean ± SEM N 382 ±39 1,38±0.43 0.58 ±0.23 3.312:0.39 23.6±5.2
T 495 ±73 0.2A±0.17J 0.30 ±0.15 4.67 ±0.47a 40.9 ±4.9“
M 565 ± 298 0.00 0.89±0.59 5.64± 1.90 57.7 ±23.3
N. normal tissue; T. tumnur; M, metastasis; - ,  not detectable; ND, not determined.
< 0.05 versus normal laryngeal mucosa.Values are given as mean ± standard error of the mean.
part of the inherent drug resistance observed in various human 
tumours (9).
Moscow et al. (22) reported a 7-fold increase in GST-tc 
mRNA levels in five squamous head and neck cancers as 
compared with adjacent normal tissue. In addition, Riou et ai
(23) found increased levels of GST-ti mRNA in squamous cell 
carcinomas of the cervix and Eimoto ei ai (24) observed 
higher GST-ti immunoreactivity in squamous cell carcinomas 
of the lung when compared with other histological types of 
lung cancer. In contrast, oesophageal squamous cell carcinomas 
had lower mean GSTtc concentrations than the surrounding 
normal tissue, but tumours with much higher GST-tc levels 
were also found (25). The head and neck squamous cell 
carcinomas analysed in the present study contained more GST 
K (-30% in oral/oropharyngeal and 40% in laryngeal tumours) 
than the surrounding normal tissue in 21 out of 25 pairs 
of samples. In laryngeal samples the differences in GST-tc 
concentrations were significant. Previously. Janot et al. (26) 
reported a slightly higher mean GST activity and GST-tc 
concentration in a limited number of normal and malignant 
specimens from the pyriform sinus of the larynx, however, 
differences did not reach significance. In a more extended 
study, Parise et ai (27) reported significantly higher GSH and 
GST enzyme activity levels in head and neck tumours as 
compared with paired control tissues.
Since GST-rc is by far the most prominent GST isoenzyme
in both normal and malignant head and neck tissue, GST 
enzyme activities are largely determined by GST-tc levels. 
Analogous to GST-ti levels, most tumours therefore contain 
more GST enzyme activity than the tissues they originated 
from (mean GST activity was almost 50% higher in oral/ 
oropharyngeal and 30% higher in laryngeal tumours), but 
differences were not significant.
Several refractory human cancers investigated contained 
elevated levels of GST-jc, suggesting a special role in drug 
resistance for this isoform (9). Studies by Lewis et al. (28) 
and Berhane et al. (29) indicate that class a  and p. GSTs may 
also be involved in anti-cancer drug resistance. However, GST- 
a  and GST-p levels were either undetectable or lower in the 
tumour tissues investigated here and it seems unlikely that 
these two GST subclasses contribute to intrinsic drug resistance 
in head and neck tumours. In contrast, GST-tc concentrations 
were higher in more than 80% of the head and neck tumours 
when compared with the adjacent normal mucosa and there­
fore this isoenzyme may mediate part of the inherent anti­
cancer drug resistance that is frequently encountered in these 
squamous cell carcinomas.
Due to a genetic polymorphism, only -55% of the Caucasian 
population has one or two functional GSTM 1 genes. Presence 
of GSTM 1-1 in smokers has been associated with a lower 
risk of squamous cell carcinoma of the lung (30,31), and 
bladder or larynx cancer (32). We did not assess smoking
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Fig. 1. Plot of calculated versus measured GST enzyme activities. Values 
are given as nmol/min/mg protein. GST enzyme activities (GST activity 
measured) was determined in all 57 samples with 1 -chloro-2,4- 
dinitrobenzene as substrate. GST activities were calculated (GST activity 
calculated) from the sum of the concentrations of GST subclasses as 
determined by immunoblot, multiplied by their specific activities with 
l-chloro-2,4-dinitrobenzene (187, 105 and 64 jumol/min/mg protein for class 
JLL, 7t and a  respectively; 8 ). Calculated GST activities = 0.94X(measured 
GST activities) +  150; correlation coefficient 0.92.
habits of our patients, but 29% of the patients with oral/ 
oropharyngeal tumours and 55% of the patients with laryngeal 
tumours were GSTM 1-1-positive. Overall, 10 of the 25 
patients (40%) did express GSTM 1 -1, which is not significantly 
different from the 55% value reported for the general population
(31). However, the characteristics of laryngeal and oral/ 
oropharyngeal tissue with respect to GST subclass composition 
are rather different and the latter group especially needs further 
study with respect to GSTM 1-1 expression.
High GSH levels may mediate resistance towards both 
radiation therapy and treatment with some anti-cancer drug 
regimens (33-35). Buthionine sulfoximine, a specific inhibitor 
of GSH synthesis, circumvents cisplatin resistance in human 
head and neck squamous cell carcinomas grown in nude mice 
(36). The high GSH levels found in most laryngeal tumours may 
therefore contribute to inherent drug and radiation resistance in 
such tumours.
Recently, Fountzilas et a i  (37) reported more complete 
responses during platinum-based chemotherapy for oral 
carcinomas than for laryngeal carcinomas; 46 and 10% respect­
ively. In the present study, laryngeal tumours were found to 
contain higher GST and GSH levels than oral/oropharyngeal 
squamous cell carcinomas, which might also be indicative of 
a role for the GST/GSH system in anti-cancer drug resistance. 
However, data on tumours which were treated with chemo­
therapeutics are required before definite conclusions can be 
drawn.
Regional neck lymph node métastasés are frequently encoun­
tered in head and neck cancer. To our knowledge no data on 
GST composition of such métastasés have been published.
The few métastasés we were able to analyse had similar GST 
and GSH levels to their primary tumours, with the exception 
of one lymph node metastasis from a laryngeal tumour, which 
contained both a very high GST activity and a very high GSH 
concentration. If GST and GSH contribute to drug and/or 
radiotherapy resistance in primary tumours, regional métastasés 
with very high levels may be even less responsive to such 
therapies.
In conclusion, GST-tc is the predominant GST subclass 
detected in both normal tissues and in human oral/oropharyn­
geal and laryngeal squamous cell carcinomas. The malignant 
tissues generally contain more GST-tc than the surrounding 
normal tissues. In addition, GSH levels were higher in laryngeal 
tumours when compared with adjacent normal tissue. These 
high GST-tc and GSH levels may occasionally be involved in 
the intrinsic drug resistance of head and neck cancers.
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